Pursuant to Regulation 30 of the SEBI (LODR) regulations 2015, We wish to inform you that the 37th Annual General Meeting (AGM) of the Members of Godavari Drugs Limited is Scheduled to ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs' board approved unaudited results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations fell sharply to Rs 23.81 crore from Rs 32.21 crore in the same quarter last year, a decline of about 26% year-on-year. Net profit dropped to Rs 1.04 crore from Rs 1.63 crore, down roughly 36% YoY, though it improved about 16% sequentially from Rs 89.31 lakh in Q4 FY25. The board also approved doubling the authorised share capital from Rs 10 crore to Rs 20 crore by creating 1 crore additional equity shares of Rs 10 each, subject to shareholder approval. Additionally, the 37th AGM was rescheduled from August 28, 2025 to September 27, 2025 to accommodate compliance timelines. The statutory auditor issued an unmodified limited review report with no qualifications.
The steep YoY decline in both revenue and profit is a negative signal for shareholders and may pressure the stock in the short term. The doubling of authorised share capital hints at a potential fundraising or equity dilution ahead, which shareholders should watch closely at the upcoming AGM.